Hidradenitis Suppurativa clinical trials at UCLA
2 in progress, 1 open to eligible people
Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
open to eligible people ages 18-100
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Sylmar 5400784, California 5332921 and other locations
Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Sorry, in progress, not accepting new patients
This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matching placebo up to Week 16.
Los Angeles 5368361, California 5332921 and other locations
Our lead scientists for Hidradenitis Suppurativa research studies include April Armstrong.
Last updated: